Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Ruxience
| Field | Information |
|---|---|
| Medication Name | Ruxience |
| Generic Name | Rituximab-pvvr |
| Boxed/Label Warning | Serious Infusion Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, Progressive Multifocal Leukoencephalopathy (PML) |
| Purpose | Treatment of certain types of cancer (non-Hodgkin’s lymphoma, chronic lymphocytic leukemia), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. |
| Mechanism of Action | A biosimilar to Rituxan; targets the CD20 protein found on B cells, leading to B cell depletion. |
| Dosage Forms | Intravenous (IV) infusion |
| Available Strengths | 10 mg/mL in 100 mg/10 mL and 500 mg/50 mL single-dose vials |
| Dosage Frequency | Varies based on condition being treated; administered in cycles. Consult prescribing information. |
| Common Side Effects | Infusion reactions (fever, chills, nausea), infections, fatigue, headache, muscle aches. |
| Serious Side Effects | Severe infusion reactions, tumor lysis syndrome, severe mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), cardiac arrhythmias, kidney toxicity. |
| Drug Interactions | Immunosuppressants, live vaccines, certain blood pressure medications, TNF inhibitors. |
| Important Notes | Administered by a healthcare professional in a medical setting; monitor for infusion reactions; increased risk of infections. Screening for Hepatitis B is required prior to starting treatment. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately to reschedule your infusion appointment. |
| Alternatives | Rituxan (rituximab), Truxima (rituximab-abbs), Hycela (rituximab and hyaluronidase human), other chemotherapeutic regimens. |
Ruxience Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Rituxan (rituximab) | Targets the CD20 protein on B cells, leading to B cell depletion. | Reference biologic; Ruxience is a biosimilar. |
| Truxima (rituximab-abbs) | Targets the CD20 protein on B cells, leading to B cell depletion. | Another biosimilar to Rituxan. |
| Hycela (rituximab and hyaluronidase human) | Rituximab targets CD20; hyaluronidase facilitates subcutaneous administration. | Subcutaneous formulation of rituximab. |
| Chemotherapeutic Regimens | Varies depending on the specific regimen. | Other chemotherapeutic options may be available for certain conditions. |
Ruxience Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Infusion reactions (fever, chills, nausea) | Severe infusion reactions (anaphylaxis) |
| Infections (upper respiratory, urinary tract) | Tumor lysis syndrome |
| Fatigue | Severe mucocutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) |
| Headache | Hepatitis B reactivation |
| Muscle aches | Progressive multifocal leukoencephalopathy (PML) |
| Low white blood cell count (neutropenia) | Cardiac arrhythmias |
| Nausea | Kidney toxicity |
Ruxience Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Non-Hodgkin’s Lymphoma | 375 mg/m² | Varies; may be given weekly or in cycles. | Administered as an IV infusion. Premedication may be required to prevent infusion reactions. Refer to prescribing information for specific regimens. |
| Chronic Lymphocytic Leukemia | Varies based on regimen. | Varies based on regimen. | Administered as an IV infusion. Premedication may be required. Refer to prescribing information. |
| Rheumatoid Arthritis | 1000 mg | 1000 mg every 6 months or based on clinical evaluation. | Administered as two 1000 mg IV infusions separated by 2 weeks. Premedication is required. |
| Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) | 375 mg/m² | 375 mg/m² weekly for 4 weeks. | Administered as an IV infusion. Premedication may be required. Followed by maintenance therapy. |
Ruxience Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $200 |
| Without Insurance (U.S.) | $3,900 |
| From CPS | $2,338 |
